Clinical trials: Hematologic Malignacies
Lymphoma, Multiple Myeloma
Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic Malignacies
Platelet concentrates (PCs) characteristics, such as storage duration, ABO compatibility, dose and source, may have an impact on transfusion responses and outcomes.
- Conditions
- Lymphoma, Multiple Myeloma, Lymphocytic Leukemia, Hodgkin Disease
- Trial name
- TCP (NCT02885038)
- Testing
- Platelet concentrate transfusion
- Volunteers
- 1,101 people
- Sponsor
- Etablissement Français du Sang
Lymphoma, Leukemia
Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
This study investigates the efficacy and safety of direct oral anticoagulants (DOACs) in comparison with standard low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in patients with hematological…
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Venous Thromboembolic Disease
- Trial name
- HEM-DOAC (NCT07270263)
- Testing
- Apixaban, Rivaroxaban, low molecular weight heparin (enoxaparin sodium)
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Gdansk
Cervical Intraepithelial Neoplasia, Cervical Neoplasms
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies
Background: Gene therapy is closely followed by the U.S. Food and Drug Administration (FDA). The FDA requires researchers to conduct long-term follow-up of people who have had the treatment.
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Neoplasms, Oropharyngeal Neoplasms, Squamous Intraepithelial Lesions of the Cervix
- Trial name
- NCT04266093
- Testing
- GeneTherapy
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Cancer Institute (NCI)
Thrombocytopenia, Hematologic Malignacies
Efficacy and Safety of MegaLT Injection for Platelet Recovery After Umbilical Cord Blood Transplantation
This is a single-arm, early safety and feasibility exploratory study to evaluate the efficacy and safety of MegaLT Injection in promoting platelet recovery after umbilical cord blood transplantation.
- Conditions
- Thrombocytopenia, Hematologic Malignacies, Platelet Recovery After Umbilical Cord Blood Transplantation
- Trial name
- NCT07696767
- Testing
- MegaLT Injection
- Volunteers
- 7 people
- Sponsor
- Anhui Provincial Hospital